stockrowExelixis, Inc. (EXEL) vs Insmed, Inc. (INSM)
- Exelixis, Inc. EXEL 69.55 +1.22%
- Insmed, Inc. INSM 114.36 +5.15%
Exelixis, Inc. and Insmed, Inc. are both Biotechnology companies. Insmed, Inc. is the larger, with a market value of $23.9B against $16.8B — 1.4× the size. Insmed, Inc. has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 19.9×. Insmed, Inc. grew revenue faster over the last twelve months: 240.0% against 9.12%. Exelixis, Inc. has the higher net margin (35.5% vs −39.9%) and the higher return on invested capital (66.6% vs −247.6%). Across the 19 metrics below, Exelixis, Inc. leads on 17 and Insmed, Inc. on 2.
Valuation
Profitability
| Metric | EXEL | INSM | Biotechnology median |
|---|---|---|---|
| Gross margin | 96.26% | 84.40% | 65.16% |
| Operating margin | 40.19% | (37.11%) | 0.00% |
| Net margin | 35.45% | (39.85%) | 0.00% |
| Free cash flow margin | 45.84% | (41.30%) | 0.00% |
| Return on equity | 44.32% | (72.45%) | (50.12%) |
| Return on assets | 33.17% | (26.41%) | (45.60%) |
| Return on invested capital | 66.59% | (247.55%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack